Clinical trial
An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With…
NCT00344383 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry · Completed
Key facts
| NCT number | NCT00344383 |
|---|---|
| Title | An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen |
| Official title | An Open-Label Study Evaluating the Bleeding Profile of Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) Administered as an Extended Regimen |
| Lead sponsor | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metrorrhagia |
| Intervention type | Drug |
| Interventions | Norgestimate/Ethinyl Estradiol tablet |
| Enrollment | 61 |
| Start date | Nov 1, 2003 |
| Completion | Jul 1, 2004 |
| First posted | Jun 26, 2006 |
| Last update posted | Mar 4, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: